Last reviewed · How we verify
Mesalazine with hydrocortisone sodium succinate — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Mesalazine with hydrocortisone sodium succinate (Mesalazine with hydrocortisone sodium succinate) — Xijing Hospital of Digestive Diseases.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mesalazine with hydrocortisone sodium succinate TARGET | Mesalazine with hydrocortisone sodium succinate | Xijing Hospital of Digestive Diseases | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mesalazine with hydrocortisone sodium succinate CI watch — RSS
- Mesalazine with hydrocortisone sodium succinate CI watch — Atom
- Mesalazine with hydrocortisone sodium succinate CI watch — JSON
- Mesalazine with hydrocortisone sodium succinate alone — RSS
Cite this brief
Drug Landscape (2026). Mesalazine with hydrocortisone sodium succinate — Competitive Intelligence Brief. https://druglandscape.com/ci/mesalazine-with-hydrocortisone-sodium-succinate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab